ClinicalTrials.gg
Active, not recruitingNCT07949175Updated Nov 19, 2026

Comprehensive Genomic Analysis of Breast Cancer With Extremely Poor Prognosis

An observational study in Breast Cancer, sponsored by Samsung Medical Center. Active, not recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Samsung Medical Center · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 47 studies in Breast Neoplasms by Samsung Medical Center — 13 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · Samsung Medical Center.

Planned enrollment
7th of 19
500 · median 400
Started
2021
with 1 other
Observational
19 of 47
6 open now
Primary completion
2030-12
later than 13 of 15 live
Registered
45th of 47
by date

Among the 47 studies in Breast Neoplasms by Samsung Medical Center, this one is the 7th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2021, is one of 19 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 45th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 47 studies in Breast Neoplasms by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Breast Neoplasms by Samsung Medical Center, or all of them as a file.
02

Study summary

Investigators conducted genomic sequencing including genome sequencing/exome sequencing/RNASeq and spatial transcriptomics of BC having dismal prognosis

Read the detailed description
  1. Sample - investigators collected samples- cancer/normal pairs from institutional biobank
  2. Tissue prep was performed
  3. Sequencing was conducted and the investigator analysed the sequencing results
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient diagnosed as Breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients who diagnosed as breast cancer

Exclusion criteria

Exclusion Criteria:

  • Patients who did not have their primary BC tissue and paired normal tissue in institutional biobank
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Breast cancer with dismal prognosis

    No intervention would be needed

06

What researchers measure

Primary outcomes

  1. Disease free survival

    Time between BC diagnosis and any recurrence

    Time frame: Through study completion, an average 3 years

  2. Disease free survival depending on genomic characteristics

    Duration between BC diagnosis and any disease recurrence detected

    Time frame: Through study completion, an average 3 years

07

Study locations

1 site
  • Samsung Bioresearch Institute
    Seoul, 06351, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2030, 119 months after the start.

Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 119 months is above that.

Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Nov 19, 2026
StartActual
Jan 21, 2021
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949175
Collaborators
Stanford University, Sungkyunkwan University, Ulsan National Institute of Science and Technology (UNIST)
Responsible party
JI-YEON, KIM (Associate Professor, Samsung Medical Center) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 21, 2021
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion